ArticleBMJ open2026

Prospective multicentre study evaluating ctDNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: NeckTAR-IN protocol.

Angeline Ginzac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.